Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 4Recruiting 3Terminated 1Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Tumor-Agnostic 1Myeloid 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Stress Disorders, Post-Traumatic 1Prostatic Neoplasms 1Neoplasms 1Kidney Neoplasms 1Colorectal Neoplasms 1

Interventions

Docetaxel 69pembrolizumab 48Prednisone 43Nivolumab 40enzalutamide 38Gemcitabine 37Sunitinib 36Cyclophosphamide 29Radiotherapy 26Magnetic Resonance Spectroscopy 26Leuprolide 25Abiraterone Acetate 25Sorafenib 23Everolimus 23Cisplatin 23bicalutamide 19atezolizumab 18Carboplatin 18Bevacizumab 18avelumab 17Radiosurgery 17Goserelin 17Interleukin-2 16abiraterone 15fludarabine 14Doxorubicin 14olaparib 13durvalumab 13cabozantinib 13acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Palliative Care × Genitourinary × Clear all
NCT03652298 2026-03-13

NeuroPrevPTSD

Centre Oscar Lambret

Phase 2 Terminated
19 enrolled
GastrointestinalGenitourinary

Urinary Bladder Neoplasms, Kidney Neoplasms, Neoplasms, Prostatic Neoplasms, Stress Disorders, Post-Traumatic, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡